TipRanks Black Friday Sale
- Claim 60% off TipRanks Premium for the data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
The latest announcement is out from MDxHealth ( (MDXH) ).
On November 12, 2025, Mdxhealth reported an 18% increase in Q3 revenues to $27.4 million and achieved an adjusted EBITDA profitability of $1.0 million. The company highlighted the strategic acquisition of Exosome Diagnostics from Bio-Techne on September 15, 2025, which is expected to enhance its market positioning by integrating the ExoDx business. Despite suspending its germline product introduction, Mdxhealth reaffirmed its full-year revenue guidance, anticipating growth to meet or exceed 20%. The acquisition and expansion of its sales organization are seen as significant steps towards capitalizing on cross-selling opportunities and strengthening its precision diagnostics offerings.
The most recent analyst rating on (MDXH) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on MDxHealth stock, see the MDXH Stock Forecast page.
Spark’s Take on MDXH Stock
According to Spark, TipRanks’ AI Analyst, MDXH is a Neutral.
MDxHealth’s score is primarily impacted by financial instability due to negative profitability and high leverage. Positive technical indicators provide some support, but valuation concerns due to negative earnings weigh on the overall score.
To see Spark’s full report on MDXH stock, click here.
More about MDxHealth
Mdxhealth is a leading precision diagnostics company that offers molecular information to personalize patient diagnosis and treatment. The company’s tests utilize proprietary genomic, epigenomic, exosomal, and other molecular technologies.
Average Trading Volume: 204,230
Technical Sentiment Signal: Hold
Current Market Cap: $219.8M
For a thorough assessment of MDXH stock, go to TipRanks’ Stock Analysis page.